Council on Foreign Relation’s “Asia Unbound”: Artemisinin’s Rocky Road to Globalization: Part II
In part two of his series on anti-malarial artemisinin drugs, Yanzhong Huang, CFR senior fellow for global health, explores the challenges China faced in marketing its artemisinin-based combination therapies worldwide. “…The 2004-2006 artemisinin bubble nevertheless has not deterred Chinese pharmaceutical firms from pursuing its globalization strategy. Supported by the state, Chinese pharmaceutical firms since 2007 have become even more aggressive in promoting their anti-malarial products globally. But how successful are their efforts? This will be the subject of my next blog post” (3/9).